Cargando…

Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study

BACKGROUND: Following each cycle of peptide receptor radionuclide therapy (PRRT), absorbed doses by tumors and normal organs are typically calculated from three quantitative single-photon emission computed tomography (SPECT)/computed tomography (CT) studies acquired at t(1) = 24 h, t(2) = 96 h, t(3)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chicheportiche, Alexandre, Sason, Moshe, Godefroy, Jeremy, Krausz, Yodphat, Zidan, Mahmoud, Oleinikov, Kira, Meirovitz, Amichay, Gross, David J., Grozinsky-Glasberg, Simona, Ben-Haim, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390741/ https://www.ncbi.nlm.nih.gov/pubmed/34436698 http://dx.doi.org/10.1186/s40658-021-00409-z

Ejemplares similares

Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
por: Chicheportiche, Alexandre, et al.
Publicado: (2020)

Predictive power of the post-treatment scans after the initial or first two courses of [(177)Lu]-DOTA-TATE
por: Chicheportiche, Alexandre, et al.
Publicado: (2018)

Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
por: Chicheportiche, Alexandre, et al.
Publicado: (2018)

Can a penalized-likelihood estimation algorithm be used to reduce the injected dose or the acquisition time in (68)Ga-DOTATATE PET/CT studies?
por: Chicheportiche, Alexandre, et al.
Publicado: (2021)

Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center’s 20 years of Experience
por: Arnon, Johnathan, et al.
Publicado: (2022)

The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid Models
por: Knigin, Adi, et al.
Publicado: (2021)

Calcitonin Non-Secreting Mixed Medullary-Papillary Thyroid Carcinoma: Report of a Rare Entity and Therapeutic Implications
por: Oleinikov, Kira, et al.
Publicado: (2021)

Clinical and pathologic characteristics of appendiceal neuroendocrine neoplasms diagnosed during pregnancy
por: Twito, Orit, et al.
Publicado: (2023)

Non-functioning pancreatic neuroendocrine tumors: Surgery or observation?
por: Bar-Moshe, Yehonatan, et al.
Publicado: (2017)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
por: Uri, Inbal, et al.
Publicado: (2018)

Towards accurate (177)Lu SPECT activity quantification and standardization using lesion-to-background voxel ratio
por: Raskin, Stanislav, et al.
Publicado: (2023)

Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease
por: Nahmias, Avital, et al.
Publicado: (2015)

Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing’s syndrome in a medullary thyroid carcinoma patient
por: Bseiso, Hashem, et al.
Publicado: (2016)

The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN
por: Alexandraki, Krystallenia I., et al.
Publicado: (2020)

Impact of dead time on quantitative (177)Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
por: Desy, Alessandro, et al.
Publicado: (2020)

Lessons Learned from Post–COVID-19 Vaccination PET/CT Studies
por: Orevi, Marina, et al.
Publicado: (2022)

Combination Therapies with PRRT
por: Yordanova, Anna, et al.
Publicado: (2021)

Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model
por: Hardiansyah, Deni, et al.
Publicado: (2022)

The PRRT2 knockout mouse recapitulates the neurological diseases associated with PRRT2 mutations
por: Michetti, Caterina, et al.
Publicado: (2017)

Quantitative SPECT/CT parameters of myocardial (99m)Technetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis
por: Ben-Haim, Simona, et al.
Publicado: (2021)

PRRT: identikit of the perfect patient
por: Albertelli, M., et al.
Publicado: (2020)

Functional study and pathogenicity classification of PRRT2 missense variants in PRRT2‐related disorders
por: Zhao, Shao‐Yun, et al.
Publicado: (2019)

A Rare Case of Cutaneous Metastasis of Bladder Transitional Cell Carcinoma
por: Fachler, Tahel, et al.
Publicado: (2021)

Cytokines levels, Severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer - a prospective pilot study
por: Meirovitz, Amichay, et al.
Publicado: (2010)

First Results and Experience with PRRT in South Africa
por: Vorster, Mariza, et al.
Publicado: (2018)

PRRT2, a network stability gene
por: Michetti, Caterina, et al.
Publicado: (2017)

New Insights in PRRT: Lessons From 2021
por: Puliani, Giulia, et al.
Publicado: (2022)

Corrigendum to ‘Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study’ [European Journal of Cancer 154 (2021) 246-252]
por: Fazio, Nicola, et al.
Publicado: (2022)

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study
por: Fazio, Nicola, et al.
Publicado: (2021)

(99m)Tc MIBI Scintigraphy for Classification of Amiodarone-induced Thyrotoxicosis
por: Itzkovich, Dror, et al.
Publicado: (2022)

Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg RET mutation in an Israeli multicenter study
por: Rosenblum, Rachel Chava, et al.
Publicado: (2023)

PRRT2 Mutant Leads to Dysfunction of Glutamate Signaling
por: Li, Ming, et al.
Publicado: (2015)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Paroxysmal Dyskinesias in a PRRT2 Mutation Carrier
por: Marano, Massimo, et al.
Publicado: (2018)

Neoadjuvant PRRT for advanced pNEN: an unusual highlander
por: Zanata, Isabella, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

Long-term prognostic factors for PRRT in neuroendocrine tumors
por: Trautwein, Nils Florian, et al.
Publicado: (2023)

Feasibility study of a novel general purpose CZT-based digital SPECT camera: initial clinical results
por: Goshen, Elinor, et al.
Publicado: (2018)

Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma
por: Hirshoren, Nir, et al.
Publicado: (2014)

Radiation-Induced Nephropathy in the Murine Model Is Ameliorated by Targeting Heparanase
por: Abecassis, Alexia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rs1qifnro06luq82mdjuq64hdc